Board of Directors
Ph.D, Director
Dr. Lin has many years of successful entrepreneurial experience and medical equipment investment fund investment and management experience, has served as the International fund China partner, executive director, co-founder, consultant to American companies. He was also served as managing director of Founder H Fund, partner of ePlanet Ventures in China, executive director of Riverhead Capital Investment and Mingly China Growth Fund, co-founder and director of Dongsheng Biotechnology, and senior consultant of McKinsey. Currently, he serves as the managing partner of YuanBio Venture Capital, leading and participating in investment projects including: CapitalBio, INNOVITA, YHLO, Rongchang Pharmaceutical, Yingsheng Biology, ikang (transfer&withdrawal), 91huayi.com (transfer&withdrawal), Miao Health, etc.
Dr. Lin received a Ph.D. in molecular biology from Columbia University School of Medicine, an MBA from the University of Chicago, and a B.S. in Biology from Peking University.
Director
Ms. Liu Yuwen is the founding partner of BOHE Angel Fund, which is the first life and health investment fund focusing on full cycle incubation in China. The company has invested in a number of leading domestic bio-pharmaceutical companies with original technological products, including Sironax founded by Wang Xiaodong, Singlomics founded by Xie Xiaoliang, Kanova founded by Dong Chen, ShuimuBio founded by Wang Hongwei, Magic med founded by Xu Xuemin, as well as Neurophth, ImmVira, ETERN and so on. Ms. Liu served as the general manager of BioBay, the deputy director of Suzhou Industrial Park Technology Investment Center, the department Manager of Suzhou Capsule Co., LTD., a Sino-American joint venture, and the chief representative of Perrigo International in Shanghai.
Ms. Liu holds a master's degree from China Pharmaceutical University and A master's degree from Fudan University School of Management. She is the founder of Beijing Bio2 and Suzhou Bohe Innovation Center.
Ph.D, President
Dr. Xu Ting has more than 20 years of experience in the research and development of bioinnovative drugs. Before returning to China, Dr. Ting Xu served as the chief researcher and project leader at Archemix, Serono and Biogen. After returning to China, Dr. Xu founded Suzhou Alphamab Oncology and Jiangsu Alphamab Oncology. (stock code: 9966.HK), and led the R&D and clinical development of 16 bio-innovative drugs of Alphamab Oncology, and promoted the listing successively.
Dr. Xu received his bachelor's degree in biochemistry from Nanjing University, doctor of Science from Institute of Biophysics, Chinese Academy of Sciences, postdoctoral fellow at Harvard University, adjunct researcher at Shanghai Institute of Materia Medica, Chinese Academy of Sciences, visiting professor at Nanjing University, and Professor of Industry at Southeast University. In recent years, he has undertaken 5 national projects including "Major New Drug Innovation". He is the co-author of more than 20 academic papers in international leading journals and the inventor of more than 100 patents.
Director
Ms. Cao Zheng has more than 10 years of investment experience in the field of biomedicine, mainly engaged in early and medium-term investment in biotechnology, medical devices, biomedicine, medical services, diagnostic technology and other fields of projects, leading and participating in investment projects including GV20 Oncotherapy, Presicion Scientific, Mid-link, Lansionbio, Reigncom Biotehcnology, Bioperfectus and other dozens of high-tech companies.
Ms. Cao holds a master's degree from Shanghai Jiao Tong University, worked for the CID group, an industry-integrated venture capital fund, co-founded Watson Investment in 2017, and served as the managing partner and executive partner of its funds. Ms. Cao Zheng is also employed by the Sichuan Research Institute and Chongqing Research Institute of Shanghai Jiao Tong University as a think-tank expert, and as an entrepreneurial mentor in Shanghai Fenglin International Group.
Founder & CEO
Mr. Ren Jianhong has more than 10 years of R&D and management experience in biotechnology, metabolomics and protein spectrum application companies. He has rich entrepreneurial experience in the biomedical industry, once worked for ProtTech in the United States, Eppendorf in Germany and other well-known multinational companies. He founded PANOMIX in 2013 and is also the co-founder of SmartNuclide, a well-known nuclear drug company.
Mr. Ren Jianhong holds a master's degree in fermentation engineering from Jiangnan University, a senior engineer, Jinji lake science and technology talents, the executive director of the Taihu Mass Spectrometry Omics and Precision Health Professional Committee of the Silk Road Industry and Finance International Alliance, the director of the Nanchang Regional Metabolomics Innovation Joint Laboratory of the Chinese Academy of Sciences, and the deputy director of the Collaborative Innovation Center for Metabolomics of Suzhou University.
© Copyright 2015-2022 Suzhou PANOMIX Biomedical Tech Co.,Ltd